Blocking a growth factor receptor cripples cancer growth in a form of T cell leukemia, according to a study published online on August 1 in the Journal of Experimental Medicine ( www.jem.org ).
Approximately half of the cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic mutations in a cellular signaling pathway called Notch, which result in aberrant activation of the cell. A study by Andrew Weng and colleagues at the British Columbia Cancer Agency now shows that activation of the Notch pathway promotes the expression of a receptor for insulin growth factor (IGF-1), which drives the growth and survival of the cancer cells.
Cancer cells with an activated Notch pathway but lacking the IGF-1 receptor had reduced growth in mice, and blocking the receptor with drugs improved their survival. Simply reducing the amount of receptor resulted in the loss of cancer stem cells—the cells responsible for originating and perpetuating the disease. Human T-ALL cells were also found to express IGF-1 receptor, suggesting that blocking the receptor in combination with standard treatment may reduce the risk of disease relapse.
About The Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org .
Medyouf, H., et al. 2011. J. Exp. Med . doi:10.1084/jem.20110121.
Journal of Experimental Medicine